AlphaFold predicted structure
GALNT2 · Q10471

Mean pLDDT
89.8/ 100
Confident
571 residues
Confidence breakdown
- Very high(≥ 90)80%
- Confident(70–90)10%
- Low(50–70)3%
- Very low(< 50)8%
AlphaFold (Jumper et al., 2021) · CC BY 4.0
polypeptide N-acetylgalactosaminyltransferase 2
Annotations refreshed 10 hours ago.
Diagnostic Grade (Green)
Congenital disorders of glycosylation
BIALLELIC, autosomal or pseudoautosomalEarly onset or syndromic epilepsy
BIALLELIC, autosomal or pseudoautosomalFetal anomalies
BIALLELIC, autosomal or pseudoautosomalInherited white matter disorders
BIALLELIC, autosomal or pseudoautosomalIntellectual disability
BIALLELIC, autosomal or pseudoautosomalLikely inborn error of metabolism
BIALLELIC, autosomal or pseudoautosomalcongenital disorder of glycosylation, type iit
metabolic syndrome
familial lipoprotein lipase deficiency
familial hyperlipidemia
alcohol drinking
insomnia
metabolic dysfunction-associated steatotic liver disease
coronary artery disorder
hyperlipidemia
physical activity
Score is the Open Targets composite evidence score (0-1). Higher = stronger gene-disease association.
Polypeptide N-acetylgalactosaminyltransferase 2
Catalyzes the initial reaction in O-linked oligosaccharide biosynthesis, the transfer of an N-acetyl-D-galactosamine residue to a serine or threonine residue on the protein receptor. Has a broad spectrum of substrates for peptides such as EA2, Muc5AC, Muc1a, Muc1b. Probably involved in O-linked glycosylation of the immunoglobulin A1 (IgA1) hinge region. Involved in O-linked glycosylation of APOC-III, ANGPTL3 and PLTP. It participates in the regulation of HDL-C metabolism (PubMed:27508872, PubMed:32293671)
GALNT2 · Q10471

Mean pLDDT
89.8/ 100
Confident
571 residues
Confidence breakdown
AlphaFold (Jumper et al., 2021) · CC BY 4.0